|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.520 - 0.548|
|52 Week Range||0.400 - 0.840|
|Beta (3Y Monthly)||-0.79|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.50|
CytoDyn Inc. (CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that Richard G. Pestell, M.D., Ph.D., President of the Pennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute Distinguished Professor, and Interim Chief Medical Officer of CytoDyn, will deliver the keynote plenary speech at the 11th Annual Conference on Stem Cell and Regenerative Medicine. Dr. Pestell’s keynote presentation, entitled “Cancer stem cells, genetic drivers and therapeutic targeting via CCR5,” will be held on Monday October 15 from 10 - 11 am EEST (GMT+3). Dr. Pestell will present recent scientific evidence for the effectiveness of PRO 140 (leronlimab) which is shown to bind to CCR5 in human breast cancer, block CCR5 signaling induced by cytokines, and block human breast cancer cell invasion.
CytoDyn Inc. (CYDY), CytoDyn unveils its strategy to complete development of PCaTest, a novel gene-based prognostic test for prostate cancer developed by ProstaGene. Following the completion of CytoDyn’s previously announced proposed acquisition of assets from ProstaGene, the Company intends to initiate a clinical study designed to further demonstrate the superiority of the PCaTest compared with current genetic tests in predicting outcomes of individuals with prostate cancer. Study results are expected within four months from the commencement of the clinical study.
A live webcast and replay of the presentation at The MicroCap Conference will be available on the Investors section of the Company’s website, http://ir.cytodyn.com/, prior to the presentation date. PRO 140 is a humanized IgG4 monoclonal antibody that blocks CCR5, a cellular receptor that plays multiple roles with implications in HIV infection, tumor metastasis, and immune signaling. PRO 140 has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects.
VANCOUVER, Washington, Sept. 11, 2018-- CytoDyn Inc. announces that management will host an investment community conference call to provide a business update.. A live audio webcast may also be accessed ...
CytoDyn Inc. (CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces its plan to develop PRO 140 (leronlimab) as a therapy for triple-negative breast cancer that has metastasized as its initial cancer indication. Previously announced findings from preclinical studies showed the ability of PRO 140 to block human breast cancer cellular invasion in a surrogate assay for metastatic breast cancer. “Triple-negative breast cells test negative for estrogen receptors (ER-), progesterone receptors (PR-) and HER2 (HER2-) and thus do not respond to hormonal therapy or therapies that target HER2 receptors. Women with this breast cancer subtype typically have a very poor prognosis and new therapies are needed,” said Richard G. Pestell, Ph.D., M.D., Interim Chief Medical Officer of CytoDyn.
CytoDyn Inc. (CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, including treatment of HIV and cancer, announces the signing of a definitive agreement to acquire privately held ProstaGene, LLC. CytoDyn also confirms that Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., Founder and Chief Executive Officer of ProstaGene, will join CytoDyn as Interim Chief Medical Officer. Upon the closing of the acquisition, which is expected in November, Dr. Pestell will become Chief Medical Officer.
CytoDyn Inc. (CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that PRO 140 (leronlimab) has been shown effective at inhibiting the growth of a human colon carcinoma cell line (SW480) in a prominent mouse model. The results were statistically significant and provide the basis for filing an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial in colon carcinoma patients. Two different strains of immunoincompetent mice were used to grow SW480 human tumor cells and different doses of PRO 140 were used in these studies.
CytoDyn Inc. (CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications in the treatment of HIV, cancer, and inflammatory conditions, announces that Michael A. Klump, President and Chief Executive Officer of Argonne Capital Group, has joined the CytoDyn Board of Directors. “We have made significant business advances in recent months with our expanded focus into cancer and immunological conditions, proposed acquisition of ProstaGene, and continued efforts toward the filing of our first Biologic License Application for PRO 140 as a combination treatment for HIV,” said Anthony D. Caracciolo, CytoDyn Chairman.
CytoDyn Inc. (CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces clearance from the independent Institutional Review Board (IRB) overseeing its CD03 Phase 3 investigative monotherapy trial to increase the weekly PRO 140 dose from 525 mg to 700 mg for newly enrolled patients. Current participants in the trial who failed to maintain suppressed HIV viral load on a lower dose of PRO 140 will be permitted to continue in the trial with a higher dose.
Glancy Prongay & Murray LLP announces an investigation on behalf of CytoDyn Inc. investors concerning the Company and its directors’ and officers’ possible violations of state laws.
NEW YORK, NY / ACCESSWIRE / February 2 2 , 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of CytoDyn Inc. (OTCQB: CYDY ) and Q Biomed Inc. (OTCQB: QBIO ...